skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology

(3334) Views  (766) Full article downloads

Authors: Kyriaki Mystakidou, Eleni Tsilika, Marinos Tsiatas, Lambros Vlahos

Published Date May 2007 Volume 2007:2(1) Pages 49 - 54
DOI: http://dx.doi.org/10.2147/IJN.S

Kyriaki Mystakidou1, Eleni Tsilika1, Marinos Tsiatas2, Lambros Vlahos3

1Pain Relief and Palliative Care Unit, Department of Radiology, Areteion Hospital, School of Medicine, University of Athens, Greece; 2Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; 3Department of Radiology, Areteion Hospital, School of Medicine, University of Athens, Athens, Greece

Abstract: Pain is experienced by most cancer patients and represents an important issue in the clinical setting. Breakthrough pain is a transitory flare of pain that occurs in most cancer patients on a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (OTFC; Actiq®, Cephalon, UK), a new opioid formulation with a unique delivery system, utilizing the advantages that nanotechnology offers, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), which makes it an effective treatment to cancer patients who are already receiving opioids and continue to experience such flares of pain. Oral transmucosal fentanyl citrate is specifically developed and approved for the management of breakthrough pain in cancer patients and it has the potential to be a useful tool for clinicians.

Keywords: oral transmucosal fentanyl citrate, cancer pain, breakthrough pain








Readers of this article also read:

Bioconjugated nanoparticle detection of respiratory syncytial virus infection
Cytotoxicity and reactive oxygen species generation from aggregated carbon and carbonaceous nanoparticulate materials
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
Is gene activity in plant cells affected by UMTS-irradiation? A whole genome approach
A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Amino acid-responsive Crohn's disease: a case study
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation